Close Menu

cancer of unknown primary

Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

Spun out of Moffitt Cancer Center, M2Gen and the Total Cancer Care protocols promise rapid advancements in precision medicine, starting with oncology.

The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.

Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

American Society of Clinical Oncology presentations show the unmet need for methods to predict autoimmune toxicities in checkpoint blockade-treated individuals.

The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.

The study will use OncoDNA's liquid biopsy tech to profile and identify treatment options for 100 patients in Lebanon, Jordan, Saudi Arabia, and the UAE.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.